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Since the adenoma-carcinoma sequence regarding colorectal cancer was revealed, endoscopic resection of precancerous lesions such as adenoma is recognized as the most important method with respect to colorectal cancer prevention. Generally, endoscopic polypectomy is a safe, easy, and convenient procedure. However, procedures are not always safe to perform. Several complications such as postcoagulation syndrome, perforation, and bleeding can occur despite best care. Among complications related with endoscopic polypectomy, postpolypectomy bleeding is the most common and undesirable situation. Although the results of each study differ slightly, the incidence of postpolypectomy bleeding is generally known to be 0.3%--6.1% \[[@b1-ce-2017-056]\]. However, considering the referral bias, the actual frequency is thought to be lower.

No consensus has been reached about the strategy to avoid postpolypectomy bleeding. First, prophylactic endoscopic management can be applied. Epinephrine containing saline injection, electric coagulation at the resection ulceration, prophylactic hemoclipping on the resection ulceration, and endoloop application are relatively popular strategies for postpolypectomy prevention. However, the effectiveness of these preventive methods has not been established yet. A retrospective study that included 1,745 patients who underwent colonoscopic polypectomy showed no benefits of endoscopic preventive methods regarding postpolypectomy bleeding \[[@b2-ce-2017-056]\]. Likewise, a meta-analysis study reported that prophylactic hemoclipping was not significant with respect to the prevention of postpolypectomy bleeding \[[@b3-ce-2017-056]\]. Another study showed that argon plasma coagulation after polypectomy did not decrease delayed bleeding \[[@b4-ce-2017-056]\]. On the contrary, a prospective randomized study that included 120 patients with 151 polyps reported that prophylactic submucosal injection before polypectomy decreased immediate postpolypectomy bleeding \[[@b5-ce-2017-056]\]. Another research group that retrospectively analyzed 524 polyps in 463 patients showed that prophylactic hemoclipping reduced delayed postpolypectomy bleeding \[[@b6-ce-2017-056]\]. Moreover, clinical importance is focused on delayed bleeding rather than on immediate bleeding. The most recent meta-analysis study showed that both mechanical and injection endoscopic preventive methods did not decrease delayed bleeding, whereas a prophylactic technique reduced immediate postpolypectomy bleeding \[[@b7-ce-2017-056]\].

Various risk factors such as large size of the polyp, location on the right colon, use of antiplatelet or anticoagulation agents, and underlying comorbidities have been identified regarding postpolypectomy bleeding. Moreover, as the prevalence of cardiovascular/neurovascular disease is increasing with the aging of the population, antithrombotic agents are highly used recently. In addition, the numbers of newly developed antithrombotic agents and dual antiplatelet therapies are increasing. Current guidelines regarding invasive endoscopic procedure in patients receiving anticoagulation agents recommend using heparin as a bridging therapy in patients at high risk of thrombosis. However, the risk of postpolypectomy bleeding does not seem to decrease even if administration of the anticoagulation agent is interrupted \[[@b8-ce-2017-056]\]. When postpolypectomy bleeding associated with heparin bridging therapy occurred, clinical presentation showed high incidence, late onset, and recurrent events that resulted in long-term hospitalization \[[@b9-ce-2017-056]\]. In this issue of *Clinical Endoscopy*, Pigò et al. retrospectively analyzed postpolypectomy bleeding, focusing on antithrombotic therapy \[[@b10-ce-2017-056]\]. Between 2007 and 2014, 118 patients with postpolypectomy bleeding were compared with 539 non-bleeding patients. Polyps larger than 10 mm, heparin use, comorbidity, and presence of 2 or more risk factors were identified as risk factors of postpolypectomy bleeding in the multivariate analysis. These results suggest that the use of heparin as a bridge therapy alone cannot eliminate bleeding associated with polypectomy. A recent similar case-control study also demonstrated that an increased postpolypectomy bleeding incidence was observed regardless of antithrombotic agent discontinuation and use of heparin bridging therapy \[[@b11-ce-2017-056]\]. Therefore, careful assessment of individual risk before polypectomy is warranted. Further study might attempt to more precisely classify the risk factors associated with various antithrombotic agents and to identify the preventive strategy related with each stratification.
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